SCYX News and Press, SCYNEXIS Inc. From 11/29/21

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its nov...

Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to placebo-treated patients. Ibrexafungerp demonstrated sustained clinical effect at Day-25 follow-up ...

Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +16%. Kornit (NASDAQ:KRNT) +15%. Aspira...

Gainers: Longeveron (NASDAQ:LGVN) +36%, SCYNEXIS (NASDAQ:SCYX) +16%, Context Therapeutics (NASDAQ:CNTX) +15%, Akoya Biosciences (NASDAQ:AKYA) +15%, Aspira Women's Health (NASDAQ:AWH) +15%. Losers: Connect Biopharma (NASDAQ:CNTB) -54%, Flora Gr...

Famed investors public positions down from 22 securities to just six. Also, closed bearish bets on bonds, but public commentary suggests that position may have been moved to a non-reporting derivative. That could explain the lower size of the reported portfolio - only positions in...

SCYNEXIS, Inc. (SCYX) Q3 2021 Earnings Conference Call November 10, 2021 8:30 a.m. ET Company Participants Debbie Etchison - Executive Director of Communications Marco Taglietti - President and Chief Executive Officer Christine Coyne - Chief Commercial Officer David Angulo - Chief Medical Off...

SCYNEXIS (NASDAQ:SCYX): Q3 GAAP EPS of -$0.06 beats by $0.67. Revenue of $0.52M beats by $0.14M. Press Release Based on a $100 million cash balance at September 30 and operating plan, SCYNEXIS has a projected cash runway into 2023. For further details see: SCYNEXIS EPS beats by $0.67, b...

BREXAFEMME ® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is continuing into Q4 with an additional 1,100 prescriptions reported in October. BREXAFEMME is now covered by commercia...

SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.70 and the consensus Revenue Estimate is $0.38M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue...

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...